Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Juno Therapeutics, Inc.
Report date July 13, 2017 · Filed July 17, 2017
Jointly reported with BRATTON DOUGLAS K, Crestline Investors, Inc., Crestline SI (GP), L.P., Crestline Management, L.P.
Section 16 reporting ended · disclosed 2017-07-17. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy CL Alaska, L.P. | 9,166,130 |
Reported balance
After 2017-07-13 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2017-07-13 · Sale · Disposed 8,000,000 · Balance 9,166,130 F1: The purchase reported in Column 4 occurred in a block transaction at a price of $27.00 per share. F2: These 9,166,130 shares of the Issuer are held directly by CL Alaska, L.P. ("CLA"). The general partner of CLA is Crestline SI (GP), L.P. ("Crestline SI") and the investment manager of CLA is Crestline Management, L.P. ("Crestline Management"). Crestline Investors, Inc. ("Crestline") is the general partner of both Crestline SI and Crestline Management. Douglas K. Bratton is the sole director of Crestline. CLA is ultimately controlled by Mr. Bratton and Mr. Bratton has voting and investment power over all of these shares of the Issuer as well as a partial pecuniary interest in the shares held by CLA. Mr. Bratton does not intend to sell additional shares of the Issuer from CLA at this time, however, please see the related disclosures in Item 4 of the Schedule 13D/A filed on June 25, 2015. F3: (Continued from footnote 2) CLA may be deemed to directly beneficially own all of these shares of the Issuer. Crestline SI, Crestline Management, Crestline and Mr. Bratton may each be deemed to indirectly beneficially own all of these shares of the Issuer. Each such entity and Mr. Bratton disclaims beneficial ownership of these shares, except to the extent of its or his respective pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy JT Line Partners LP | 182,669 |
Reported balance
Holding disclosure · report date 2017-07-13 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 182,669 F4: The shares of the Issuer reported in Column 5 are held directly by JT Line Partners LP ("JT"). The general partner of JT is Bratton Capital Management L.P. ("Bratton Capital Management"). The general partner of Bratton Capital Management is Bratton Capital, Inc. ("Bratton Capital"). Douglas K. Bratton is the sole director of Bratton Capital. JT is ultimately controlled by Mr. Bratton and Mr. Bratton has voting and investment power over all of the shares of the Issuer held by JT, as well as a partial pecuniary interest in such shares. JT directly beneficially owns these shares of the Issuer. Bratton Capital Management, Bratton Capital and Mr. Bratton may each be deemed to indirectly beneficially own the shares of the Issuer held by JT. Each such entity and Mr. Bratton disclaims beneficial ownership of these shares, except to the extent of its or his respective pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The purchase reported in Column 4 occurred in a block transaction at a price of $27.00 per share.
F2: These 9,166,130 shares of the Issuer are held directly by CL Alaska, L.P. ("CLA"). The general partner of CLA is Crestline SI (GP), L.P. ("Crestline SI") and the investment manager of CLA is Crestline Management, L.P. ("Crestline Management"). Crestline Investors, Inc. ("Crestline") is the general partner of both Crestline SI and Crestline Management. Douglas K. Bratton is the sole director of Crestline. CLA is ultimately controlled by Mr. Bratton and Mr. Bratton has voting and investment power over all of these shares of the Issuer as well as a partial pecuniary interest in the shares held by CLA. Mr. Bratton does not intend to sell additional shares of the Issuer from CLA at this time, however, please see the related disclosures in Item 4 of the Schedule 13D/A filed on June 25, 2015.
F3: (Continued from footnote 2) CLA may be deemed to directly beneficially own all of these shares of the Issuer. Crestline SI, Crestline Management, Crestline and Mr. Bratton may each be deemed to indirectly beneficially own all of these shares of the Issuer. Each such entity and Mr. Bratton disclaims beneficial ownership of these shares, except to the extent of its or his respective pecuniary interest therein.
F4: The shares of the Issuer reported in Column 5 are held directly by JT Line Partners LP ("JT"). The general partner of JT is Bratton Capital Management L.P. ("Bratton Capital Management"). The general partner of Bratton Capital Management is Bratton Capital, Inc. ("Bratton Capital"). Douglas K. Bratton is the sole director of Bratton Capital. JT is ultimately controlled by Mr. Bratton and Mr. Bratton has voting and investment power over all of the shares of the Issuer held by JT, as well as a partial pecuniary interest in such shares. JT directly beneficially owns these shares of the Issuer. Bratton Capital Management, Bratton Capital and Mr. Bratton may each be deemed to indirectly beneficially own the shares of the Issuer held by JT. Each such entity and Mr. Bratton disclaims beneficial ownership of these shares, except to the extent of its or his respective pecuniary interest therein.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 13, 2017 Filed Jul 17, 2017 17:48 UTC | Juno Therapeutics, Inc. JUNO · Entity 168572 | SaleCommon Stock | 8,000,000 | $27.00 | $216,000,000.00 |
DisclosureSEC source: 0000899243-17-018338 · doc4.xml · nonDerivative · entry 1 BRATTON DOUGLAS K · CIK 0001281933 · 10% owner Crestline Investors, Inc. · CIK 0001626596 · 10% owner Crestline SI (GP), L.P. · CIK 0001626597 · 10% owner Crestline Management, LP · CIK 0001536054 · 10% owner CL Alaska, L.P. · CIK 0001626595 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By CL Alaska, L.P. Disclosed balance after: 9,166,130 F1 · shares: The purchase reported in Column 4 occurred in a block transaction at a price of $27.00 per share. F2 · ownership.nature: These 9,166,130 shares of the Issuer are held directly by CL Alaska, L.P. ("CLA"). The general partner of CLA is Crestline SI (GP), L.P. ("Crestline SI") and the investment manager of CLA is Crestline Management, L.P. ("Crestline Management"). Crestline Investors, Inc. ("Crestline") is the general partner of both Crestline SI and Crestline Management. Douglas K. Bratton is the sole director of Crestline. CLA is ultimately controlled by Mr. Bratton and Mr. Bratton has voting and investment power over all of these shares of the Issuer as well as a partial pecuniary interest in the shares held by CLA. Mr. Bratton does not intend to sell additional shares of the Issuer from CLA at this time, however, please see the related disclosures in Item 4 of the Schedule 13D/A filed on June 25, 2015. F3 · ownership.nature: (Continued from footnote 2) CLA may be deemed to directly beneficially own all of these shares of the Issuer. Crestline SI, Crestline Management, Crestline and Mr. Bratton may each be deemed to indirectly beneficially own all of these shares of the Issuer. Each such entity and Mr. Bratton disclaims beneficial ownership of these shares, except to the extent of its or his respective pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.